Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients
Open accessThe DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
CTLA-4 blockade induces T cell repertoire turnover, but high-frequency clonotypes are maintained in patients with favorable outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“patients with castration-resistant prostate cancer or advanced melanoma who maintained their oligoclonal circulating baseline TCRs after receiving anti-CTLA-4 responded better to therapy than those in which more of those clonotypes were lost (163).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [163]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Read, S., Malmström, V., & Powrie, F. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,205
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195
Similarity indices, sample size and diversity
Wolda, H. (1981) · Oecologia · doi:10.1007/bf00344966 · Cited by 1,104
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Krummel, M. F., & Allison, J. P. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.6.2533 · Cited by 932
Selby, M. J., Engelhardt, J. J., Quigley, M., Henning, K. A., Chen, T., Srinivasan, M., & Korman, A. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0013 · Cited by 857
van Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798 · cited 2×
“Recent works have shown that tumor-reactive neoantigen-specific T cells can be identified from tumor samples by exome analysis (45, 46).”
BackgroundResultAn immune-active tumor microenvironment favors clinical response to ipilimumab
Ji, R.-R., Chasalow, S. D., Wang, L., Hamid, O., Schmidt, H., Cogswell, J., Alaparthy, S., Berman, D., Jure-Kunkel, M., Siemers, N. O., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1172-6 · Cited by 775
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 2×
“Disruption of CTLA-4 and B7 interactions by mAbs with ipilimumab or tremelimumab enhances both Teff and Treg proliferation, leading to suggestions that a ratio favoring Teffs over Tregs would promote tumor regression (4, 16).”
BackgroundSlovin, S. F., Higano, C. S., Hamid, O., Tejwani, S., Harzstark, A., Alumkal, J. J., Scher, H. I., Chin, K., Gagnier, P., McHenry, M. B., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt107 · Cited by 559
Egen, J. G., & Allison, J. P. (2002) · Immunity · doi:10.1016/s1074-7613(01)00259-x · Cited by 535
Hamid, O., Schmidt, H., Nissan, A., Ridolfi, L., Aamdal, S., Hansson, J., Guida, M., Hyams, D. M., Gómez, H., Bastholt, L., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-204 · Cited by 534 · cited 1×
“The potential importance of baseline T cell fitness is underscored by factors that have been associated with clinical benefit from ipilimumab and are suggestive of T cell activation and/or proliferation upon treatment with CTLA-4 blockade: elevated absolute lymphocyte counts (17), expression of inflammatory immune-rel…”
BackgroundBulliard, Y., Jolicoeur, R., Windman, M., Rue, S. M., Ettenberg, S., Knee, D. A., Wilson, N. S., Dranoff, G., & Brogdon, J. L. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130573 · Cited by 446
Ku, G. Y., Yuan, J., Page, D. B., Schroeder, S. E. A., Panageas, K. S., Carvajal, R. D., Chapman, P. B., Schwartz, G. K., Allison, J. P., & Wolchok, J. D. (2010) · Cancer · doi:10.1002/cncr.24951 · Cited by 422
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 407
Self-citationOverlap and Effective Size of the Human CD8 + T Cell Receptor Repertoire
Robins, H. S., Srivastava, S. K., Campregher, P. V., Turtle, C. J., Andriesen, J., Riddell, S. R., Carlson, C. S., & Warren, E. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001442 · Cited by 383
Yuan, J., Adamow, M., Ginsberg, B. A., Rasalan, T. S., Ritter, E., Gallardo, H. F., Xu, Y., Pogoriler, E., Terzulli, S. L., Kuk, D., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110814108 · Cited by 332
Direct Link Between mhc Polymorphism, T Cell Avidity, and Diversity in Immune Defense
Messaoudi, I., Patiño, J. A. G., Dyall, R., LeMaoult, J., & Nikolich-Žugich, J. (2002) · Science · doi:10.1126/science.1076064 · Cited by 323
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
Wolchok, J. D., Hodi, F. S., Weber, J. S., Allison, J. P., Urba, W. J., Robert, C., O'Day, S. J., Hoos, A., Humphrey, R., Berman, D. M., et al. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12180 · Cited by 303
T Cell Receptor Recognition Motifs Govern Immune Escape Patterns in Acute SIV Infection
Price, D. A., West, S. M., Betts, M. R., Ruff, L. E., Brenchley, J. M., Ambrozak, D. R., Edghill-Smith, Y., Kuroda, M. J., Bogdan, D., Kunstman, K., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.10.010 · Cited by 272
Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., Allison, J. P., Small, E. J., & Fong, L. (2008) · Blood · doi:10.1182/blood-2007-11-125435 · Cited by 256 · cited 1×
“Disruption of CTLA-4 and B7 interactions by mAbs with ipilimumab or tremelimumab enhances both Teff and Treg proliferation, leading to suggestions that a ratio favoring Teffs over Tregs would promote tumor regression (4, 16).”
BackgroundSelf-citationFong, L., Kwek, S. S., O'Brien, S., Kavanagh, B., McNeel, D. G., Weinberg, V., Lin, A. M., Rosenberg, J., Ryan, C. J., Rini, B. I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3529 · Cited by 246
Self-citationTrautmann, L., Rimbert, M., Echasserieau, K., Saulquin, X., Neveu, B., Dechanet, J., Cerundolo, V., & Bonneville, M. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.9.6123 · Cited by 224
Measuring of interspecific association and similarity between communities
Morisita, M. (1959) · Nihon Seitai Gakkaishi · Cited by 209
Immunosequencing: applications of immune repertoire deep sequencing
Robins, H. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.09.017 · Cited by 198
CTLA4 blockade increases Th17 cells in patients with metastatic melanoma
von Euw, E., Chodon, T., Attar, N., Jalil, J., Koya, R. C., Comin-Anduix, B., & Ribas, A. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-35 · Cited by 189
Self-citationA Molecular Basis for the Control of Preimmune Escape Variants by HIV-Specific CD8+ T Cells
Ladell, K., Hashimoto, M., Iglesias, M. C., Wilmann, P. G., McLaren, J. E., Gras, S., Chikata, T., Kuse, N., Fastenackels, S., Gostick, E., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.021 · Cited by 164
Ribas, A., Hanson, D. C., Noe, D. A., Millham, R., Guyot, D. J., Bernstein, S. H., Canniff, P. C., Sharma, A., & Gomez-Navarro, J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-7-873 · Cited by 161
Self-citationAndrogen Receptor Specifically Interacts with a Novel p21-activated Kinase, PAK6
Yang, F., Li, X., Sharma, M., Zarnegar, M., Lim, B., & Sun, Z. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010311200 · Cited by 157
Day, E. K., Carmichael, A. J., ten Berge, I. J. M., Waller, E. C. P., Sissons, J. G. P., & Wills, M. R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3203 · Cited by 153
Biomarkers on melanoma patient T Cells associated with ipilimumab treatment
Wang, W., Yu, D., Sarnaik, A. A., Yu, B., Hall, M., Morelli, D., Zhang, Y., Zhao, X., & Weber, J. S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-146 · Cited by 120
Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H. E., Scholten, P. E. T., Reijm, M., Jooss, K. U., Sacks, N., Hege, K. M., Lowy, I., et al. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1330-5 · Cited by 97
Comin-Anduix, B., Lee, Y., Jalil, J., Algazi, A., de la Rocha, P., Camacho, L. H., Bozon, V. A., Bulanhagui, C. A., Seja, E., Villanueva, A., et al. (2008) · Journal of Translational Medicine · doi:10.1186/1479-5876-6-22 · Cited by 82
Self-citationKwek, S. S., Dao, V. A., Roy, R., Hou, Y., Alajajian, D., Simko, J. P., Small, E. J., & Fong, L. H. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1201529 · Cited by 74
Self-citationSpeiser, D. E., Baumgaertner, P., Barbey, C., Rubio-Godoy, V., Moulin, A., Corthesy, P., Devevre, E., Dietrich, P.-Y., Rimoldi, D., Liénard, D., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1338 · Cited by 68
Unmasking the immune recognition of prostate cancer with CTLA4 blockade
Kwek, S. S., Cha, E., & Fong, L. H. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3223 · Cited by 60
Self-citationKlinger, M., Kong, K. A., Moorhead, M., Weng, L., Zheng, J., & Faham, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074231 · Cited by 40
Self-citationRini, B. I., Fong, L. H., WEINBERG, V. K., Kavanaugh, B., & Small, E. J. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(06)00261-8 · Cited by 34
Self-citationModulation of Cell Signaling Networks after CTLA4 Blockade in Patients with Metastatic Melanoma
Comín-Anduix, B., Sazegar, H., Chodon, T., Matsunaga, D. R., Jalil, J., von Euw, E., Escuin-Ordinas, H., BALDERAS, R. S., Chmielowski, B., Gómez-Navarro, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012711 · Cited by 31
Self-citationMiles, J. J., Silins, S. L., Brööks, A. G., Davis, J. E., MISKO, I. S., & Burrows, S. R. (2005) · Blood · doi:10.1182/blood-2005-06-2261 · Cited by 30
Derré, L., Bruyninx, M., Baumgaertner, P., Devêvre, E., Corthésy, P., Touvrey, C., Mahnke, Y. D., Pircher, H., Voelter, V., Romero, P. J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.4.2368 · Cited by 27
CMV driven CD8+ T-cell activation is associated with acute rejection in lung transplantation
Roux, A., Mourin, G., Fastenackels, S., Almeida, J. R., Iglesias, M. C., Boyd, A. C., Emma Gostick, D., Larsen, M., Price, D. A., Sacré, K., et al. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.03.012 · Cited by 26
Cited by
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Self-citationFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
“Anti-CTLA4 predominantly inhibits Tregs, increasing the CD8/Treg ratio as previously described 17 , and results in modest peripheral expansion of TCR clonotypes in the tumor, also consistent with other reports 18,19 .”
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
“An immediate turnover of the T-cell repertoire on initial treatment was shown, and it continued to evolve with further treatment; both expansion and loss of individual T-cell clonotypes were identified, but there was a net increase in TCR diversity.(46) Overall survival, however, was associated with the maintenance of…”
BackgroundBagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Metadata
- Authors
- Cha, E., Klinger, M., Hou, Y., Cummings, C., Ribas, A., Faham, M., & Fong, L.
- Affiliations
- University of California, San Francisco (US)
- Sequenta, South San Francisco, CA 94080, USA.
- University of California, Los Angeles (US)
- Corresponding author
- Fong, Lawrence
- Venue
- Science Translational Medicine
- Published
- 2014-05-28
- Volume
- 6
- Issue
- 238
- Pages
- 238ra70-238ra70
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC4558099
- OpenAlex
- W1998927848
- Cited by
- 383
- References
- 51
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 21 · 2023: 21 · 2022: 38 · 2021: 41 · 2020: 42 · 2019: 44 · 2018: 38 · 2017: 35 · 2016: 40 · 2015: 31 · 2014: 12
- FWCI
- 19.00
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (5r01ca136753-05)
- National Cancer Institute (1R01 CA136753, R01CA163012, R01-CA136753)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, T cell receptor repertoire, TCR diversity, metastatic castration-resistant prostate cancer, metastatic melanoma, antitumor immunity, overall survival, immune checkpoint inhibitors
- MeSH terms
- Antibodies, Monoclonal, Humans, Neoplasms, Survival Analysis, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.